Texas A&M Basketball

Lunch with Liucci: Billy Liucci joins TexAgs Live (Friday, December 20)

TexAgs' co-owner and executive editor Billy Liucci joined TexAgs Live on Friday morning as Texas A&M stays active in the transfer portal. Liucci discussed what a pair of tight end transfers mean for the offense, Wade Taylor IV's legacy as an Aggie and much more.
By Billy Liucci
December 20, 2024
4.9k Views
Discuss
Story Poster
Photo by Zoe Kelton, TexAgs

TexAgs' co-owner and executive editor Billy Liucci joined TexAgs Live on Friday morning as Texas A&M stays active in the transfer portal. Liucci discussed what a pair of tight end transfers mean for the offense, Wade Taylor IV's legacy as an Aggie and much more.


Segment 1 (00:00:00 - 07:40:18)

  • I completely agree with J.J. Watt. I would rather talk than text. It is not a common thing anymore.
To view this content, you must be a TexAgs Premium subscriber.
Get Premium for $1
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial
Discuss
Tags
TexAgs Live David Nuño Bernard King Donald Sloan 12th Man Foundation TexAgs Live Feature Acie Law Alex Caruso Lunch with Liucci Tyler Davis Joseph Jones J.J. Watt
Show All
Antoine Wright Joe Lunardi Nic Anderson Kelby Collins Mario Craver Micah Hudson Kevin Concepcion Micah Riley Nate Boerkircher Texas A&M vs. Houston Christian Albert Regis Shemar Turner Wade Taylor IV DJ Hicks Shemar Stewart Nic Scourton Dealyn Evans Theo Melin-Öhrström Rylan Kennedy Solomon Williams Cashius Howell Football Basketball Texas A&M Houston Christian 2024
SPONSORED BY
12th Man Foundation
More Basketball
See All →
Monaco says A&M's talent, depth continue to stand out in 8-0 start
By David Nuño
5 Thoughts: Texas A&M 104, Texas Southern 70
By Luke Evangelist
Photo Gallery: A&M uses second-half surge to smash Texas Southern
By Will Huffman
Game Highlights: Texas A&M 104, Texas Southern 70
By TexAgs
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.